CURACLE Submits IND to U.S. FDA for Phase 2b Trial of Oral Retinal Disease Drug CU06
- Input
- 2026-11-20 13:50:23
- Updated
- 2026-11-20 13:50:23

CURACLE is a drug development company that develops treatments for intractable and age-related diseases, including retinal, kidney and thrombotic diseases, based on its platform technology for normalizing vascular function.
The Phase 2b trial will involve 156 patients with edema in the central part of the macula and best-corrected visual acuity (BCVA) of 25–69 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Patients will be randomly assigned to the CU06 200 mg group, the 300 mg group or the placebo group, and will take the medication once a day for 24 weeks. The primary endpoint is the change in BCVA at week 24 from before treatment; this will be compared with the placebo group to assess CU06’s effect on improving vision.
The trial was designed to focus on patients with low vision, who showed particularly notable effects in the earlier Phase 2a trial. CURACLE completed a Phase 2a trial involving 67 patients with diabetic macular edema at 11 clinical trial sites in the United States. An analysis of the subgroup of patients who completed the trial according to protocol and had a baseline BCVA of 69 letters or less found that the CU06 300 mg group showed an average improvement of about six letters in visual acuity after 12 weeks. For comparison, a 2022 study that pooled real-world data on existing anti-VEGF injections reported an average visual acuity gain of about five letters one year after treatment began.
CU06 is an oral Endothelial Dysfunction Blocker developed independently by CURACLE and is a first-in-class drug candidate. It aims to preserve and improve visual function by enhancing vascular barrier function and protecting retinal nerve cells.
Retinal disease is currently treated primarily by directly injecting anti-VEGF drugs into the eye to block vascular endothelial growth factor (VEGF) signaling. Because treatment must continue over a long period, patients have to contend with fear of injections into the eye, pain and discomfort after injections, and the time and cost of repeated hospital visits. This has led to sustained demand for treatments that reduce the burden of administration through oral medication and make ongoing treatment possible.
CURACLE refined its follow-up development strategy after a Type C meeting with the FDA last year and has been preparing the trial in collaboration with outside experts. Trial operations will be handled by Syneos Health, a global contract research organization (CRO) with extensive clinical trial experience in retinal diseases.
A CURACLE representative said, “We plan to more closely assess the vision-improvement effect and safety observed in the Phase 2a trial and select the appropriate dose for Phase 3.” The representative added, “We will provide a new option in the form of an oral treatment for patients who find repeated injections into the eye burdensome.”
[email protected] Jung Sang-hee Reporter